Invivoscribe’s Subsidiary LabPMM Gets NY State Approval for NPM1 MRD Leukemia Test

Invivoscribe’s Subsidiary Received Approval

Image Credits: Invivoscribe

Announcement

Invivoscribe proudly announced its subsidiary’s Laboratory for Personalized Molecular Medicine (LabPMM) approval from the New York State (NYS) for the NPM1 MRD assay. The approval of the subsidiary was received two months after receiving NYS approval for our company’s FLT3 ITD MRD assay. These two tests are a complex tool for pharmaceutical companies, clinicians, and patients having myeloid leukemia (AML). This approval has strengthened Invivoscribe’s commitment to serving appropriate standardized, measurable residual disease (MRD) testing solutions globally.

How do New Tests Impact Treatment and Expand Development in the Healthcare Market?

The innovation and introduction of new tests are improving patient care and accelerating the healthcare market. The newly approved molecular test, NPM1 MRD assay. The multiple curing factors for AML and cancer treatment are raising demand for this testing. The approval of this test is a new hope for AML variants and cancer patients. It is a tool, playing a crucial role in providing information for long-term monitoring and treatment decisions. The healthcare market discovers severe diseases and challenges, to which the continuous need for development and introduction to innovation is an important factor in the healthcare sector.

New Assay

The NPM1 MRD is a flourishing development against AML, providing an ultra-sensitive DNA sequencing method to properly calculate trace levels of residual leukemia cells in patients suffering from the NPM1 mutation variants. LabPMM is strengthened after the approval, and it's further contributing to initiating positive change in the landscape of drug development, AML research, and treatment. MRD stimulation in clinical trials, instead of depending on overall survival (OS), the pharmaceutical companies can leverage their drug development quickly. This is effective in acute diseases.

This treatment selection for patients suffering from AML is provided by the European Union, Asia, and the US. This regional approach is initiated to enable standardized testing and contribute to the development of cancer treatment. LabPMM will continue to deliver precision medicine and enhance patient outcomes.

Views and Statements

VP global clinical laboratory operations at LabPMM, Jordan Thornes, said, “The company is feeling very proud to receive NYS approval for NPM1 MRD Assay by NGS. It’s our second assay to be approved by NYS this year. This is a milestone highlighting our efforts to develop an accurate diagnostic tool in cancer care. This approval encouraged us to develop clinicians by availing the required and advanced tools, detecting residual diseases, and guiding treatment decisions with precision.”